Review
Introduction
Rationale
Objectives
Methods
Protocol
Eligibility criteria
Inclusion criteria
Exclusion criteria
Information sources
Search
Study selection
Data collection process
Data items
Risk of bias in individual studies
Summary measures
Synthesis of results
Additional analyses
Results
Study selection
Study characteristics
Risk of bias within studies
Author | Year of publication | Study design | Outcome measure | Criteria—survival | Criteria—success | Quality assessment using the MINORS assessment tool | Head and neck cancer diagnosis | Patients age range | Follow-up period | Implant site | Implant system | Implant placement protocol | Prosthodontic rehabilitation |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Studies with an average follow-up of 3 years or greater | |||||||||||||
Watzinger et al. [29] | 1996 | Retrospective observational | Implant survival in irradiated mandibles and Outcomes of Peri-implant bone | Not defined | N/A | 7/16 | SCC | Range = 41–79 years | Up to 3 years | Mandible | IMZ | Primary and secondary implant placement. Secondary placement 6 months after oncological reconstruction. Delayed loading of implants of at least 6 months. | Removable |
Teoh et al. [26] | 2005 | Retrospective observational | Implant survival in the reconstructed mandible and prognostic factors. | Own—implant not removed then survived. | N/A | 12/16 | SCC, Osteogenic sarcoma, Benign tumours, mucoepidermoid carcinoma and other sarcomas | Mean = 42 years (range = 67–80.5 years) | Mean = 51.7 months (range = 1.3–138 months) | Mandible | Nobel and Osseotite | Delayed loading of implants 6 months after placement. Fixations screws removed prior to implant placement | Fixed and removable |
Wu et al. [30] | 2008 | Retrospective observational | Clinical outcomes of dental implants placed in fibula free flaps for orofacial reconstruction | Own—implants still functioning with no mobility, pain or infection, but with peri-implant bone resorption more than 2 mm were classified as survived. | Albrektsson et al.1986 | 9/16 | Benign and malignant head and neck tumours | Average 47.1 years | Average 47.8 months | Maxilla and mandible | ITI and Branemark | 19 patients had primary implant placement 10 patients had secondary placement after oncological reconstruction. Delayed loading of implants of at least 3 months after placement. | Fixed and removable |
Fenlon et al. [19] | 2012 | Retrospective observational | Implant survival | Poorly defined—implant osseointegrated and in situ then survived (usefulness of implant assessed using own 4-point index) | N/A | 12/16 | Cancer | Unknown | At least 3 years | Unknown | Nobel Biocare, Endopore, Astra and unknown implants | 95 implants were primarily placed and 50 implants had secondary placement 3 months after oncological reconstruction. | Unknown |
Ch’ng et al. [20] | 2014 | Retrospective observational | Implant survival, assess effect of risk factors associated with poor healing. | N/A | Own—implant success was defined as a painless and stable fixture without evidence of peri-implant infection or radiographic lack of osseointegration | 12/16 | SCC, recurrence, osteosarcoma, desmoid tumour, adenoid cystic carcinoma, adenocarcinoma, fibrosarcoma, melanoma, MEC, hemangioma-endotheiloma | Median age = 59 years | Mean = 3.1 years | Unknown | Astra | Primary and secondary implant placement. Patients had implants placed prior to radiotherapy. Reconstruction plates and screws removed if hindering implant placement. Debulking of soft tissues and vestibuloplasty also carried out as required. | All removable |
Shaw et al. [31] | 2005 | Retrospective observational | Implant survival and complications and surgical complications | N/A | Own—implant success was defined as remaining function, no mobility, pain or infection. | 10/16 | 80% of patients SCC, other 20% unknown | Mean = 58 year (range = 15–80 years) | Mean = 3.5 years (range = 0.3/14 years) | Maxilla and mandible | Frialit II, IMZ, Branemark, and IMTEC | Secondary implant placement 1 year after oncological reconstruction. Delayed loading of implants of 3–6 months. Debulking of soft tissue and mucosal grafts carried out as required. | Fixed and removable |
Wang et al. [21] | 2015 | Retrospective observational | Vertical bone Height—double barrel vs vertical distraction Osteogenesis in Fibula Free Flaps, Implant Survival and Success | Poorly defined - implant still in situ then survived. | Albrektsson et al.1986 | 12/16 | Ameloblastoma and OKC | Range = 28–55 years | Mean = 42.5 months ± 4 months | Mandible | Straumann | Secondary implant placement after oncological reconstruction. Delayed loading of implants 3-5 months after placement. Distraction osteogenesis devices used as implants and restored. | All fixed |
Yerit et al. [16] | 2006 | Retrospective observational | Implant survival in the mandible after radiotherapy and radical surgery in oral cancer patients. | N/A | Own - Implant Success when no complaints of the patient, no mobility, no peri-implant tissue inflammation and no peri-implant bone loss exceeding one-third of implant length was observed | 10/16 | Cancer of oral cavity (majority of the subjects having destructive oral squamous cell carcinomas stage T2–T4) | Range = 16–84.1 years | Mean = 5.42 years ± 3.21 years | Mandible | IMZ, Frialit II and Xive | Implant insertion at various intervals with the mean at 1.41 years after reconstruction. Delayed loading of implants of at least 6 months. Gingivoplasty and vestibuloplaty procedures carried out as required. | Removable |
Linsen et al. [17] | 2009 | Retrospective observational | Survival of implants and implant-retained prostheses in patients after ablative surgery of oral cancer with or without adjunctive radiation therapy. | N/A | Kaplan et al. 1958 | 9/16 | SCC, Ameloblastoma, Adenoid Cystic Carcinoma, OKC, Carcinoma of other origins | Mean = 55.7 year (range = ± 16.25 years) | Mean = 47.99 months ± 134.31 months) | unknown | Branemark and Straumann | Delayed implant placement with an average of 41 months after oncological treatment. Delayed loading of implants of 4.9 months (average). | Fixed and removable |
Studies with an average follow-up of less than 3 years or no average follow-up reported | |||||||||||||
Fierz et al. [25] | 2013 | Retrospective observational | Reports on surgical and prosthodontic rehabilitation after resection for oral oncology resection | Own—implant not removed then survived, those functioning given a ‘survival rating’ | N/A | 9/16 | SCC, Adenocarcinoma and Others tumours | Mean = 57 year (range = ± 7.2 years) | Range = Less than 12 months up to 5 years | Maxilla and Mandible | Unknown | No described protocol. | Fixed and removable |
Barrowman et al. [7] | 2011 | Retrospective observational | Audit experience of implant placement in jaws after oral cancer resection, Success of Prosthodontic Rehabilitation | Poorly defined - implant still in situ then survived | N/A | 10/16 | SCC, Verrucous Carcinoma, Osteosarcoma and Adenoid Cystic Carcinoma | Range = 20–76 years | Up to 15 years | Maxilla and Mandible | Branemark | No described protocol. | Fixed and removable |
Zou et al. [22] | 2013 | Retrospective observational | Long-term clinical outcomes on immediate or staged Implant Placement in iliac bone for restoring defects after tumour resection. | Own - Implants provided supportive function and were stable when torque tested | Albrektsson et al.1986 | 7/16 | SCC, Ameloblastoma, OKC, Myxoma | Range = 24–61 years | Up to 12 years | Mandible | Nobel and Straumann | 17 patients had primary implant placement 15 patients had secondary placement after oncological reconstruction. Delayed loading of implants of 5–6 months. Bone condensing was performed to enhance the bone density. | Fixed and removable |
Schultes et al. [15] | 2002 | Retrospective observational | Stability of implants in microvascular free flaps | Poorly defined - implant still in situ then survived | N/A | 8/16 | Alveolar crest carcinoma T4 | Average 58.2, 53.6 years | Up to 12 months | Mandible | SIS (Austria) | Implants placed 4 months after radiotherapy Delayed loading of implants of 4 months | All removable |
Buddula et al. [24] | 2010 | Retrospective observational | Implant survival in irradiated bone | Own—implant present in oral cavity at time of data collection then deemed to have survived. | N/A | 13/16 | SCC, adenoid cystic carcinoma, BCC and unknown | Mean = 60.2 years | Up to 7 years | Maxilla and mandible | Unknown | Median time from ending radiotherapy to implant placement was 3.4 years. | Unknown |
Klein et al. [32] | 2009 | Retrospective observational | Prognostic parameters for the rehabilitation of mandibular continuity defects with free autologous bone and dental implants for patients after intra-oral squamous cell carcinoma | N/A | Naert et al. 1992 | 11/16 | SCC | Mean = 55.7 years | Not documented | Mandible | Unknown | Implants were principally placed into the following 4 tissue conditions: non-irradiated local bone, irradiated local bone, osteoplastic in non-irradiated tissue and osteoplastic in irradiated tissue. | Unknown |
Burgess et al. [27] | 2017 | Retrospective observational | Implant survival in a variety of composite free flaps | Own—implant not removed then survived | N/A | 10/16 | Head and neck neoplasia | Average age at implantation was 51 years (range, 18–77 years) | At least 6 months follow-up | Maxilla and mandible | Neoss, Straumann Dentsply Sirona, South Africa - Head Office implants | Primary and secondary implant placement. The mean time to implant placement from reconstruction was 19 months (range, 0–141 months) with 2 patients (7 implants) having their implants placed into the fibula 6 weeks before harvesting. | Unknown |
Chiapasco et al. [18] | 2006 | Retrospective observational | Fibula Free flap survival, implant survival | Albrektsson et al.1986 | Albrektsson et al.1986 | 9/16 | Rhabdomyosarcoma, sarcoma, SCC, osteosarcoma and ameloblastoma | Range = 13–66 years | Range = 24–106 months | Maxilla and mandible | Branemark, ITI and 3i | Placement using surgical guides. Secondary implant placement 3–12 months after oncological reconstruction. Implants immediately loaded in 2 patients. Delayed loading for the all other patients 3-6 months after placement. | Fixed and removable |
Chiapasco et al. [23] | 2008 | Retrospective observational | Bone graft success, implant success, patient satisfaction | Own—similar to Albrektsson et al.1986 authors allow greater bone loss around implants. | Albrektsson et al.1986 | 7/16 | Ameloblastoma, ossifying fibroma, cementoblastoma, myxoma, SCC, gigantocellular tumour, OKC and rhabdomyosarcoma. | Range = 17–54 years | Range = 48–132 months | Mandible | Straumann, Nobel biocare and Branemark | Placement using surgical guides. Secondary implant placement 4–7 months after oncological reconstruction. Delayed loading of implants 4-6 months after placement. | All fixed |
Chiapasco et al. [33] | 2000 | Retrospective observational | Bone resorption of bone grafts, behaviour of bone around implants, implant failure | Albrektsson et al.1986 | Albrektsson et al.1986 | 10/16 | Ewing sarcoma, epidermoid carcinoma, cylindroma, desmoplastic fybroma, chondroblastic sarcoma, cementoblastoma, ameloblastoma, chondrosarcoma, ossifying fibroma, myxoma and giantocellular tumour | Range = 20–58 years | Range = 14–34 months | Maxilla and mandible | Branemark and ITI | Placement using surgical guides. Secondary implant placement 4–8 months after oncological reconstruction. Delayed loading of implants 4-6 months after placement. | Unknown |
Hessling et al. [28] | 2015 | Retrospective observational | Implant survival, peri-implantitis | Poorly defined—implant still in situ then survived. | N/A | 8/16 | SCC and odontogenic tumours with malignant degeneration | Range = 18–77 years | Range = 3–82 months | Maxilla and mandible | Xive and templant | No described protocol. | Fixed and removable |
Statistical analysis
Results of the studies
Implant survival | Implant success | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Author | Year of publication | Donor site of autogenous bone graft | Radiotherapy/chemotherapy to bone graft site | Complications | |||||||||
No. of patients who had implants placed into autogenous bone grafts (and failures) | Overall patient implant survival in autogenous bone grafts | No. of implants placed into autogenous bone grafts (and failures) | Overall implant survival in autogenous bone grafts | No. of patients who had implants placed into autogenous bone grafts (and unsuccessful) | Overall patient implant success in autogenous bone grafts | No. of implants placed into autogenous bone grafts (and unsuccessful) | Overall implant success in autogenous bone grafts | Reasons for a lack of implant success | |||||
Studies with an average follow-up of 3 years or greater | |||||||||||||
Watzinger et al. [29] | 1996 | Vascularised iliac bone graft and non-vascularised iliac and rib bone graft | Yes—all patients had chemotherapy and RDX | Marginal bone loss, periodontal pocketing, gingival index and sulcus bleeding index showed wide variation | Not reported | N/A | 52 (14) | 73.1%* | Not reported | N/A | 52 (22) | 57.7%* | Non-functioning implants (not prosthetically loaded) |
Teoh et al. [26] | 2005 | Vascularised fibula free flap | Yes—5 patients had chemotherapy, 1 patients had chemo/RDX (pre-implant placement), 6 patients had pre-op RDX and 1 patient had post-op RDX. | 13 patients had soft tissue hyperplasia that need debulking or skin grafting | 22 (2) | 90.9%* | 71 (3) | 95.8%* | Not reported | N/A | Not reported | N/A | N/A |
Wu et al. [30] | 2008 | Fibula free flap | Yes—3 patients had RDX (unsure if pre or post-op) | Soft tissue hyperplasia needed surgical removal in 6 patients (17 implants). | 29 (not reported) | N/A | 100 (9) | 91.0% | 29 (not reported) | N/A | 100 (14) | 86.0% | Unfavourable local soft tissue and implant left as sleepers. Peri-implant bone loss greater than 2 mm |
Fenlon et al. [19] | 2012 | Vascularised free flap—DCIA, radial, fibula and rib | Yes—35 implants had RDX | High rate of poor implant positioning in primary implant placement. | 41 (10) | 75.6%* | 145 (18) | 87.5%* | Not reported | N/A | 145 (34) | 76.6%* | Implants osseointegrated but prosthetically unusable |
Ch’ng et al. [20] | 2014 | Vascularised fibula free flap | Yes −66/243 patients had RDX (43 patients pre-op RDX, 23 patients post-op RDX) | ORN 7.7% of all implants (19 patients, 4 cases in vascularised fibula free flap and 15 in native bone) smoking was shown to be a significant risk factors. Also modification of peri-implant soft tissue required such as debulking of soft tissue and vestibuloplasty as required. | 54 (10) | 81.5%* | 243 (20) | 91.8% | Not reported | N/A | Not reported | N/A | N/A |
Shaw et al. [31] | 2005 | Vascularised composite DCIA, fibula and radius and non-vascularised bone grafts | Yes—47% of patients had RDX | Soft tissue overgrowth in 3 patients (5 implants). Also, surgical debulk of soft tissue reported in number of cases. | 33 (12) | 63.6%* | 123 (32) | 69.0% | Not reported | N/A | Not reported | N/A | N/A |
Wang et al. [21] | 2015 | Vascularised fibula free flap (double barrel or vertical distraction osteogenesis techniques) | NO | Implant hygiene and bleeding increased over time. 6 patients (11 implants) required soft tissue reduction however recurrence of soft tissue overgrowth occurred. | 19 (0) | 100% | 51 (0) | 100%* | Not reported | N/A | 51 (7) | 86.3%* | Peri-implant bone loss greater than criteria (radiographic assessment) |
Yerit et al. [16] | 2006 | Vascularised and non-vascularised iliac bone graft | No—No RDX to bone graft sites | None noted only documenting causes of implant loss | Not reported | N/A | 78 (13) | 54.0% | Not reported | N/A | Not reported | N/A | N/A |
Linsen et al. [17] | 2009 | Avascularised iliac bone graft | Yes—39 implants had RDX, 44 implants did not have RDX | Peri-implantitis in 12 patients (31 implants). | Not reported | N/A | 79 (8) | 89.9%* | Not reported | N/A | Not reported | N/A | N/A |
Studies with an average follow-up of less than 3 years or no average follow-up reported | |||||||||||||
Fierz et al. [25] | 2013 | Vascularised free flap—fibula, radius, scapula | Yes—20 out of 46 implants had RDX | Frail patients limited treatment, and prosthetic rehabilitation was challenging | Not reported | N/A | 46 (8) | 82.6%* | Not reported | N/A | Not reported | N/A | N/A |
Barrowman et al. [7] | 2011 | Vascularised free flap—illiac, DCIA and fibula and non-vascularised bone graft. | Yes—15 implants in to irradiated vascularised free flap | Inability of patients to tolerate prosthesis. Peri-implantitis and lack of integration of some implants. | Not reported | N/A | 38 (5) | 86.8%* | Not reported | N/A | Not reported | N/A | N/A |
Zou et al. [22] | 2013 | Vascularised iliac bone graft | No | Increase in plaque index over time. Prosthodontic complications overtime after prosthesis fitted also tumour recurrence | 32 (not reported) | N/A | 110 (4) | 96.4% | Not reported | N/A | 110 (9) | 91.8% | Severe gingival hyperplasia and bone resorption in peri-implant area |
Schultes et al. [15] | 2002 | Vascularised scapula and iliac bone graft | Yes—all patients had RDX 60 Gys. | Increased pocket depth around implants placed into non-native bone in comparison to native bone. 7 implants with pocketing greater than 5 mm were all in vascularised free flaps | 38 (2) | 94.7%* | 96 (2) | 97.9%* | Not reported | N/A | 96 (4) | 95.8%* | Implants inadequately positioned and could not be used for further prosthetic treatment |
Buddula et al. [24] | 2010 | Bone graft—fibula, iliac and scapula (unsure of vascularised or non-vascularised) | Yes—all patients had RDX | None noted only documenting implant survival | Not reported | N/A | 59 (8) | 83.3% | Not reported | N/A | Not reported | N/A | N/A |
Klein et al. [32] | 2009 | Avascular iliac bone graft | Yes—some patients had RDX | None noted only documenting implant survival | Not reported | N/A | 128 (22) | 78.4% | Not reported | N/A | Not reported | N/A | N/A |
Burgess et al. [27] | 2017 | Vascularized bone grafts—fibula, DCIA, scapula and radial | Yes—some patients had RDX | None noted only documenting implant survival | 59 (not reported) | N/A | 199 (11) | 93.6% | Not reported | N/A | Not reported | N/A | N/A |
Chiapasco et al. [18] | 2006 | Vascularised fibula free flap | Yes—some patients had RDX and chemo—unknown number | Soft tissue overgrowth in 2 patients that required removal and palatal mucosal graft placed | 14 (1) | 92.9%* | 62 (1) | 98.3%* | 14 (2) | 85.7%* | 62 (5) | 91.9%* | Peri-implant bone loss greater than criteria (radiographic assessment) |
Chiapasco et al. [23] | 2008 | Non-vascularised—Calvarium or iliac bone graft | Unknown | Soft tissue grafting required around implants in 3 patients | 16 (1) | 93.8%* | 60 (2) | 96.7% | 16 (2) | 87.5%* | 60 (4) | 93.3% | Peri-implant bone loss greater than criteria (radiographic assessment) |
Chiapasco et al. [33] | 2000 | Non-vascularised—ilieum and fibula, and vascularised free flap—ilieum and fibula | Yes—3 patients had RDX (unknown if pre or post) | Soft tissue grafting required around implants in 3 patients | 18 (2) | 88.9%* | 72 (3) | 95.8%* | 18 (2) | 88.9%* | 72 (3) | 95.8%* | N/A |
Hessling et al. [28] | 2015 | Free iliac crest, microvascular iliac, microvascular fibula, microvascular scapula, calavarial bone graft | Yes—some patients had RDX and chemo (pre- and post-op) unknown number | 67% peri-implantitis due to a lack of attached gingivae | Not reported | N/A | 93 (8) | 91.4%* | Not reported | N/A | Not reported | N/A | N/A |
Non-vascularised bone graft | Vascularised bone graft | ||||||||
---|---|---|---|---|---|---|---|---|---|
Author | Year of publication | No. of patients who had implants placed into non-vascularised autogenous bone grafts (and failures) | Overall patient implant survival in non-vascularised autogenous bone grafts | No. of implants placed into non-vascularised autogenous bone grafts (and failures) | Overall implant survival in non-vascularised autogenous bone grafts | No. of patients who had implants placed into vascularized autogenous bone grafts (and failures) | Overall patient implant survival in vascularised autogenous bone grafts | No. of implants placed into vascularised autogenous bone grafts (and failures) | Overall implant survival in vascularised autogenous bone grafts |
Studies with an average follow-up of 3 years or greater | |||||||||
Watzinger et al. [29] | 1996 | Not reported | N/A | 33 (13) | 60.6%* | Not reported | N/A | 19 (1) | 94.7%* |
Teoh et al. [26] | 2005 | N/A | N/A | N/A | N/A | 22 (2) | 90.9%* | 71 (3) | 95.8%* |
Wu et al. [30] | 2008 | N/A | N/A | N/A | N/A | 29 (not reported) | N/A | 100 (9) | 91% |
Fenlon et al. [19] | 2012 | N/A | N/A | N/A | N/A | 41 (10) | 75.6%* | 145 (18) | 87.5%* |
Ch’ng et al. [20] | 2014 | N/A | N/A | N/A | N/A | 54 (10) | 81.5%* | 243 (20) | 91.8% |
Shaw et al. [31] | 2005 | 2 (1) | 50%* | 8 (2) | 75%* | 31 (11) | 64.5%* | 115 (30) | 73.9%* |
Wang et al. [21] | 2015 | N/A | N/A | N/A | N/A | 19 (0) | 100% | 51 (0) | 100%* |
Yerit et al. [16] | 2006 | Not reported | N/A | Not reported | N/A | Not reported | N/A | Not reported | N/A |
Linsen et al. [17] | 2009 | Not reported | N/A | 79 (8) | 89.9%* | N/A | N/A | N/A | N/A |
Studies with an average follow-up of less than 3 years or no average follow-up reported | |||||||||
Fierz et al. [25] | 2013 | N/A | N/A | N/A | N/A | Not reported | N/A | Not reported | N/A |
Barrowman et al. [7] | 2011 | Not reported | N/A | 6 (0) | 100%* | Not reported | N/A | 32 (5) | 84.4%* |
Zou et al. [22] | 2013 | N/A | N/A | N/A | N/A | 32 (not reported) | N/A | 110 (5) | 96.4% |
Schultes et al. [15] | 2002 | N/A | N/A | N/A | N/A | 38 (2) | 94.7%* | 96 (2) | 97.9%* |
Buddula et al. [24] | 2010 | Not reported | N/A | Not reported | N/A | Not reported | N/A | Not reported | N/A |
Klein et al. [32] | 2009 | Not reported | N/A | 128 (22) | 82.8%* | N/A | N/A | N/A | N/A |
Burgess et al. [27] | 2017 | N/A | N/A | N/A | N/A | 59 (not reported) | N/A | 199 (11) | 93.6% |
Chiapasco et al. [18] | 2006 | N/A | N/A | N/A | N/A | 14 (1) | 92.9%* | 62 (1) | 98.3%* |
Chiapasco et al. [23] | 2008 | 16 (1) | 93.8%* | 60 (2) | 96.7%* | N/A | N/A | N/A | N/A |
Chiapasco et al. [33] | 2000 | 10 (1) | 90%* | 41 (2) | 95.1%* | 8 (1) | 87.5%* | 31 (1) | 96.8%* |
Hessling et al. [28] | 2015 | Not Reported | N/A | 62 (4) | 93.5%* | Not reported | N/A | 31 (4) | 87.1%* |
Overall implant survival
Autogenous bone graft type and implant survival
Radiotherapy and implant survival
RDX | No RDX | ||||||||
---|---|---|---|---|---|---|---|---|---|
Author | Year of publication | No. of implants placed into autogenous bone grafts with RDX (and failures) | Overall implant survival of implants placed into autogenous bone grafts with RDX | No. of patients who had implants placed into autogenous bone grafts with RDX (and failures) | Patient based implant survival of implant placed into autogenous bone grafts with RDX | No. of implants placed into autogenous bone grafts with no RDX (and failures) | Overall implant survival of implants placed into autogenous bone grafts with no RDX | No. of patients who had implants placed into autogenous bone grafts with no RDX (and failures) | Patient-based implant survival of implant placed into autogenous bone grafts with no RDX |
Teoh et al. [26] | 2005 | 14(2) | 85.7%* | 4 (1) | 75%* | 57 (1) | 98.2%* | 22 (1) | 95.4%* |
Fenlon et al. [19] | 2012 | 35 (15) | 57.1%* | 12 (8) | 33.3%* | 110 (3) | 97.3%* | 29 (2) | 93.1%* |
Ch’ng et al. [20] | 2014 | 66 (11) | 83.3%* | Not reported | N/A | 177 (9) | 94.9%* | Not reported | N/A |
Fierz et al. [25] | 2013 | 20 (6) | 70.0%* | Not reported | N/A | 26 (2) | 92.3%* | Not reported | N/A |
Barrowman et al. [7] | 2011 | 15 (5) | 66.7%* | Not reported | N/A | 23 (0) | 100%* | Not reported | N/A |
Buddula et al. [24] | 2010 | 59 (8) | 83.3% | Not reported | N/A | N/A | N/A | N/A | N/A |
Burgess et al. [27] | 2017 | 45* (7) | 84.4%* | Not reported | N/A | 154 (4) | 97.4%* | Not reported | N/A |